Compare RVYL & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | BMRA |
|---|---|---|
| Founded | 2007 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.0M |
| IPO Year | 2008 | 1995 |
| Metric | RVYL | BMRA |
|---|---|---|
| Price | $7.81 | $2.33 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.2K | 17.0K |
| Earning Date | 04-15-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,131,000.00 | $5,311,000.00 |
| Revenue This Year | $770.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $1.87 |
| 52 Week High | $8.55 | $4.60 |
| Indicator | RVYL | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 59.04 |
| Support Level | $5.00 | $2.12 |
| Resistance Level | $8.55 | $2.40 |
| Average True Range (ATR) | 0.65 | 0.07 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 96.06 | 61.56 |
Ryvyl Inc is a financial technology company that provides payment acceptance and disbursement solutions, mainly enabling merchants to process credit card transactions through BIN sponsorship arrangements with acquiring banks and payment processors, where it operates as an intermediary performing functions such as merchant underwriting, onboarding, risk monitoring, and customer support. The company also offers its internally developed NEMS Core platform, which facilitates automated inbound and outbound disbursements through a modular workflow system.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.